Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis

This article has been corrected. Please see J Manag Care Spec Pharm. 2019;25(2):285-86. BACKGROUND: Cystic fibrosis (CF) is a chronic, progressive, genetic disease affecting more than 30,000 people in the United States and 70,000 people globally. The goals of treatment are to slow disease progressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Vadagam, Pratyusha, Kamal, Khalid M., Covvey, Jordan R., Giannetti, Vincent, Mukherjee, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397671/
https://www.ncbi.nlm.nih.gov/pubmed/30247102
http://dx.doi.org/10.18553/jmcp.2018.24.10.987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397671/
https://www.ncbi.nlm.nih.gov/pubmed/30247102
http://dx.doi.org/10.18553/jmcp.2018.24.10.987

Ejemplares similares